F-1: Check-Cap Pivots to AI with MBody AI Merger, Secures $30M Funding

Check-Cap Ltd. is undergoing a significant transformation, merging with MBody AI Corp. to become an embodied AI software company, while also securing a $30 million equity purchase agreement with ARC Group International Ltd.

Summary

• Check-Cap Ltd. (MBAI) is registering up to 2,267,857 ordinary shares for resale by ARC Group International Ltd., comprising 2,000,000 Advance Shares and 267,857 Commitment Fee Shares.
• The company entered into a Purchase Agreement with ARC Group International Ltd. on December 17, 2025, allowing Check-Cap to sell up to $30.0 million of its ordinary shares over a three-year period.
• As consideration for ARC Group's commitment, Check-Cap issued 267,857 Commitment Fee Shares, valued at 1.5% of the total commitment amount, without cash payment from ARC Group.
• Check-Cap will not receive proceeds from ARC Group's resale of shares, but may receive up to $30.0 million in gross proceeds from its own sales to ARC Group under the Purchase Agreement, to be used for working capital and general corporate purposes.
• The company is undergoing a reverse merger with MBody AI Corp., an artificial intelligence company, which is expected to close in the first half of 2026.
• Post-merger, former MBody AI equityholders are expected to own approximately 90% and former Check-Cap equityholders approximately 10% of the combined company on a fully diluted basis.
• The combined company will be renamed MBody AI Ltd., and its ticker symbol was changed from CHEK to MBAI on December 1, 2025.
• Check-Cap's previous business combination agreement with Nobul AI Corp. will be terminated upon the MBody AI merger, with outstanding loans to Nobul converting into a 7.5% equity position in Nobul for Check-Cap.
• MBody AI focuses on developing hardware-agnostic embodied AI software platforms for autonomous systems, initially targeting the hospitality industry with potential expansion into warehousing, office management, and healthcare.
• MBody AI operates on an AI-as-a-Service business model, generating recurring subscription revenue, and has commercial arrangements with two Fortune 500 hospitality companies.
• Check-Cap received a Nasdaq deficiency letter on September 3, 2025, for not maintaining minimum shareholders' equity of $2,500,000, and submitted a plan to regain compliance on October 20, 2025.
• The company undertakes to seek shareholder approval at its next annual general meeting to re-designate its Ordinary Shares as no-par value shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as a highly speculative and transformative event. While the capital commitment and pivot to AI offer potential, the significant dilution for existing shareholders, MBody AI's limited operating history, and ongoing Nasdaq compliance issues present substantial risks.

Positives

• Secured a potential $30.0 million equity financing facility through the Purchase Agreement with ARC Group International Ltd., providing a source of capital for future operations.
• The strategic pivot to MBody AI's embodied AI software business offers a new growth avenue in a rapidly expanding technology sector, moving away from a struggling medical diagnostics focus.
• MBody AI has already established commercial arrangements with two Fortune 500 hospitality companies and other enterprise customers, indicating early market traction.
• The AI-as-a-Service business model is designed for recurring subscription revenue, which can provide more predictable income streams compared to one-time sales.

Negatives

• Existing Check-Cap shareholders will experience substantial dilution, with former MBody AI equityholders expected to own approximately 90% of the combined company post-merger.
• Check-Cap's legacy medical diagnostics business has been significantly scaled back, including a workforce reduction and discontinuation of calibration studies, indicating past operational challenges.
• The company received a Nasdaq deficiency letter for failing to meet minimum shareholders' equity requirements, posing a risk of delisting.
• MBody AI has a limited operating history (incorporated October 2024) and a history of operating losses, making its future prospects uncertain.
• The Purchase Agreement allows the company to sell shares at a discount to market price, which could further dilute shareholders.
• The company has incurred and expects to continue incurring substantial transaction-related costs in connection with the Merger.

Risks

• It is not possible to predict the actual number of shares sold under the Purchase Agreement or the gross proceeds, which could be substantially less than the $30.0 million commitment.
• Future sales and issuances of Ordinary Shares, including those under the Purchase Agreement, might result in significant dilution and could cause the share price to decline.
• The company may require additional financing to sustain operations, and such financing may not be available on acceptable terms or at all.
• Management will have broad discretion over the use of proceeds from the Purchase Agreement, and these uses may not improve financial condition or market value.
• There is no assurance that the proposal to re-designate Ordinary Shares as no-par value will be completed, which could limit flexibility to issue shares.
• The company may be unable to maintain compliance with Nasdaq's continued listing requirements, potentially leading to delisting and reduced liquidity.
• The issuance of Ordinary Shares in connection with the Merger will substantially dilute the relative voting power of pre-Merger Check-Cap shareholders.
• The company may fail to realize the anticipated benefits of the Merger, or it may take longer than expected.
• The company may become involved in securities litigation or shareholder derivative litigation, diverting management attention and harming the business (already involved in Nobul BCA related litigation).
• MBody AI's limited operating history and evolving business model make it difficult to evaluate its future prospects and ensure sustainable growth or profitability.
• MBody AI relies on a limited number of customers, and the loss or reduction of business from any customer could materially adversely affect its results.
• The phased and evolving feature set of MBody AI's platform may affect the timing and scope of customer adoption, with no assurance all planned features will be completed or integrated on schedule.
• MBody AI's operations depend on third-party vendors, deployment partners, and hardware suppliers, exposing it to procurement, integration, supply chain, financing, and maintenance risks.
• Complex implementation and service delivery for MBody AI may expose it to operational risks, increased costs, or contractual disputes.
• Customer adoption, ROI, and budget cycles could adversely affect MBody AI's revenue and growth.
• Deployments of MBody AI's platform depend on customer-controlled facilities and operating environments, which are outside of its control.
• Integration with third-party software and systems for MBody AI's platform may increase deployment costs, delay implementations, or reduce customer satisfaction.
• MBody AI operates in regulated environments (hospitality, gaming, healthcare) and may be subject to regulatory requirements that could increase costs or limit growth.
• MBody AI may face liability or compliance exposure related to the operation of autonomous systems, even though it does not manufacture hardware.
• The regulatory landscape for artificial intelligence, robotics, and autonomous systems is evolving and may adversely affect MBody AI's business.
• MBody AI has a history of operating losses and may not achieve or sustain profitability.
• MBody AI will require additional capital to execute its business plan, and such capital may not be available on acceptable terms.
• Future financings for MBody AI may result in dilution and could adversely affect shareholders.
• MBody AI operates in a rapidly evolving and competitive market, with new technologies and competitors potentially reducing demand.
• MBody AI's success depends on its ability to attract and retain key personnel.
• As a foreign private issuer, the combined company will follow certain home country corporate governance practices instead of Nasdaq requirements, potentially offering less protection to U.S. investors.
• Enforceability of civil liabilities against the Israeli-incorporated company and its non-U.S. directors/officers in U.S. courts may be difficult.

Future Outlook

The Merger with MBody AI Corp. is expected to consummate in the first half of 2026, subject to various conditions including sufficient capital and regulatory approvals. Upon closing, the combined company will change its name to MBody AI Ltd. and continue MBody AI's business of developing embodied AI software platforms, while Check-Cap's legacy business will continue essential research and development activities and hold its legacy assets. MBody AI intends to expand its software platform and customer deployments, believing in the increasing adoption of AI and automation technologies across labor-intensive industries.

Management Comments

• Management believes that continued innovation in artificial intelligence and automation technologies is expected to influence a wide range of industries over time, and MBody AI intends to participate in this evolving market through the expansion of its software platform and customer deployments.
• Management believes that embodied AI solutions have potential applications across multiple large and diverse industries, including hospitality, warehousing, office facilities, and healthcare, and that adoption of such technologies remains at an early stage in many markets.

Industry Context

StockSavvy.ai notes that Check-Cap's strategic pivot from medical diagnostics to embodied AI via the MBody AI merger aligns with the broader industry trend of increasing investment and innovation in artificial intelligence and automation. Many companies are seeking AI-driven solutions to address rising labor costs and operational complexities. MBody AI's focus on an AI-as-a-Service model is consistent with the growing preference for subscription-based software solutions in enterprise technology. However, the embodied AI market is rapidly evolving and highly competitive, requiring continuous innovation and significant capital, which MBody AI's limited operating history and reliance on third-party hardware and partners could challenge.

Comparison to Industry Standards

• The 90% dilution for existing Check-Cap shareholders in the MBody AI merger is a substantial transfer of ownership, typical of reverse mergers where a struggling public shell acquires a more promising private entity, but it is on the higher end of dilution seen in such transactions, indicating the relative value and potential of MBody AI compared to Check-Cap's legacy business.
• MBody AI's AI-as-a-Service model is comparable to other enterprise software companies in the AI space, such as UiPath (RPA automation) or C3.ai (enterprise AI platform), which also focus on recurring revenue streams rather than hardware sales. However, MBody AI's specific focus on 'embodied AI' for autonomous systems in physical environments (e.g., hospitality robotics) positions it in a niche that is still nascent compared to broader AI applications.
• The reliance on third-party hardware vendors and deployment partners for MBody AI's platform is a common strategy in the robotics and automation industry (e.g., Boston Dynamics, Locus Robotics often partner with integrators), allowing MBody AI to focus on its core software competency. However, this also introduces supply chain and integration risks that could impact deployment timelines and costs, similar to challenges faced by other hardware-dependent software providers.
• MBody AI's engagement with Fortune 500 hospitality companies for initial commercial deployments suggests a targeted market entry strategy, similar to how early-stage enterprise tech companies often secure anchor clients to validate their technology and business model.

Corporate Governance

Legal Proceedings

• The company is currently involved in shareholder derivative litigation relating to the Nobul BCA.

Related Party Transactions

• Upon the closing of the Merger, the loans made by Check-Cap to Nobul that are currently outstanding will be converted into a 7.5% equity position in Nobul that will be owned by Check-Cap, and each of the related loan agreements between the Company and Nobul will be cancelled for no further consideration.

Stakeholder Impact

• Shareholders (pre-Merger Check-Cap): Will experience significant dilution, owning approximately 10% of the combined company post-Merger, and face potential further dilution from sales under the Purchase Agreement.
• Shareholders (general): Face risks of market price decline and volatility due to potential future share sales and the highly speculative nature of the new business.
• Employees: Check-Cap announced a significant workforce reduction on June 6, 2023, impacting its legacy medical diagnostics operations.
• Creditors: The company's ability to meet obligations is a concern, as indicated by the Nasdaq deficiency related to shareholders' equity and the need for additional financing.

Next Steps

• The Merger with MBody AI Corp. is expected to consummate in the first half of 2026.
• The company will continue to conduct its legacy business, focusing on essential research and development activities and holding legacy assets.
• The combined company intends to continue advancing MBody AI's platform and leverage public company infrastructure for future development and commercialization.
• The company will include a proposal to amend its amended articles of association to re-designate the Ordinary Shares as no-par value shares on the agenda for its next annual general meeting of shareholders.
• The company must regain compliance with Nasdaq's minimum shareholders' equity requirement to avoid delisting.

Key Dates

Recommendation

The filing outlines a highly speculative and dilutive transformation for Check-Cap. Existing shareholders face immediate and substantial dilution (90% ownership transfer to MBody AI equityholders) and further potential dilution from the $30 million equity purchase agreement. While the pivot to AI offers a new direction, MBody AI has a limited operating history, a history of losses, and significant operational and regulatory risks. The company also has ongoing Nasdaq listing compliance issues and a 'going concern' explanatory paragraph in its 2024 Annual Report. For current shareholders, the significant dilution and high uncertainty surrounding the new business, coupled with past struggles, suggest a 'sell' to mitigate further risk, unless they have a very high risk tolerance and strong conviction in MBody AI's long-term, unproven potential.

Keywords

MBody AI, Check-Cap, AI-as-a-Service, Embodied AI, Autonomous Systems, Reverse Merger, Equity Financing, Nasdaq Listing, Dilution, SEC Filing, F-1 Registration, Corporate Governance, Risk Factors, Medical Diagnostics, Hospitality Technology